WadwaRP, LaffelL, ShahV, GargSK: Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10 days of use in youth and adults with diabetes. Diabetes Technol Ther, 2018; 20:395–402.
3.
ShahV, LaffelL, WadwaRP, GargSK: Performance of a factory—calibrated, real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther, 2018; 20:428–433.
4.
GargS, AkturkH: The future of continuous glucose monitoring. Diabetes Technol Ther, 2017; 19(Suppl. 3):S1–S2.
5.
BergenstalRM, GargS, WeinzimerSA, et al: Safety of a hybrid closed-loop insulin delivery system in type 1 diabetes (T1D). JAMA, 2016; 316:1407–1408.
6.
GargS, WeinzimerSA, TamborlaneWV, et al: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
7.
GargSK, StrumphP: Effects of Sotagliflozin added to insulin in type 1 diabetes. N Engl J Med, 2018; 378:967–968.
8.
BuseJB, GargSK, RosenstockJ, et al.: Sotagliflozn in combination with optimized insulin therapy in adults with type 1 diabetes: the North American in Tandem1 Study. Diabetes Care, 2018; 41:1970–1980.
9.
DandonaP, MathieuC, PhillipM, et al.: DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicenter, double-blind, phase 3 randomised controlled trial. Lancet Diabetes Endocrinol, 2017; 5):864–876.
10.
RosenstockJ, MarguardJ, LaffelLM, et al.: Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE Trials. Diabetes Care, 2018; 41:2560–2569.
HusainM, BirkenfeldAL, DonsmarkM, et al.; for the PIONEER 6 Investigators: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2019; 381:841–851.
13.
PerkovicV, JardineMJ, NealB, et al.; for the CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 2019; 380:2295–2306.
14.
MarsoSP, BainSC, ConsoliA, et al.; for the SUSTAIN-6 Investigators: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016; 375:1834–1844.
15.
DaviesMJ, D'AlessioDA, FradkinJ, et al.: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018; 41:2669–2701.
16.
FosterNC, BeckRW, MillerKM, et al.: State of type 1 diabetes management and outcomes from T1D Exchange in 2016–2018. Diabetes Technol Ther, 2019; 21:66–72.
17.
BeckRW, BrownSA, LumJW, KovatchevBP: Nonadjunctive use of continuous glucose monitoring: the end of fingersticks? Diabetes Technol Ther 2020;22 [Epub ahead of print]; DOI: 10.1089/dia.2019.0387.
18.
BattelinoT, DanneT, BergenstalRM, et al.: Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care, 2019; 42:1593–1603.
19.
BeckRW, BergenstalRM, LaffelLM, PickupJC: Advances in technology for management of type 1 diabetes. Lancet, 2019; 394:1265–1273.
20.
Rama ChandranS, VigerskyR, ThomasA, et al.: Role of composite glycemic indices: a comparison of the comprehensive glucose pentagon (CGP) across diabetes types and HbA1c levels. Diabetes Technol Ther, 2020; 22; DOI:10.1089/dia.2019.0277.
21.
ZhouJ, LuJ, MaX, et al.: Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther, 2020;22 [Epub ahead of print]; DOI: 10.1089/dia.2019.0251.
22.
BrownSA, KovatchevBP, RaghinaruD, et al.; for the iDCL Trial Research Group: Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381:1707–1717.
23.
DavisA, KuriakoseJ, ClementsJN: Faster insulin aspart: a new bolus option for diabetes mellitus. Clin Pharmacokinet, 2019; 58:421–430.
24.
KlonoffD, BodeB, CohenN, et al.: Divergent hypoglycemic effects of hepatic-directed prandial insulin: a six-month phase 2b study in type 1 diabetes. Diabetes Care, 2019; 42:2154–2157.
FriasJP, NauckMA, VanJ, et al.: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet, 2018; 392:2180–2193.
27.
PettusJH, ZhouFL, ShepherdL, et al.: Incidences of severe hypoglycemia and diabetic ketoacidosis and prevalence of microvascular complications stratified by age and glycemic control in U.S. adult patients with type 1 diabetes: a real-world study. Diabetes Care, 2019; 42:2220–2227.
28.
ZhongVW, JuhaeriJ, Mayer-DavisEJ: Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care, 2018; 41:1870–1877.
29.
KazemianP, SheblFM, McCannN, et al.: Evaluation of the cascade of diabetes care in the United States, 2005–2016. JAMA Intern Med 2019 [Epub ahead of print]; DOI: 10.1001/jamainternmed.2019.2396.
30.
RawshaniA, RawshaniA, FranzénS, et al.: Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med, 2017; 376:1407–1418.
31.
RawshaniA, SattarN, FranzénS, et al.: Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet, 2018; 392:477–486.
32.
SussmanM, BennerJ, HallerM, et al.: Estimated lifetime economic burden of type 1 diabetes. Diabetes Technol Ther, 2020; 22:121–130.
33.
GargS: The “economic health” of U.S. healthcare and role of middlemen. Diabetes Technol Ther, 2020; 22:136–141.
34.
GargS, AkturkHK: A new era in continuous glucose monitoring: food and Drug Administration creates a new category of factory-calibrated non-adjunctive, interoperable class II medical devices. Diabetes Technol Ther, 2018; 20:391–394.
35.
KovatchevB, ChengP, AndersonSM, et al.: Feasibility of long term closed loop control: a Multicenter 6-month trial of 24/7 automated insulin delivery. Diabetes Technol Ther, 2017; 19:18–24.
36.
BuckinghamBA, ForlenzaGP, PinskerJE, et al.: Safety and feasibility of the OmniPod hybrid closed-loop system in adult, adolescent and pediatric patients with type 1 diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther, 2018; 20:257–262.
37.
ReddyM, JugneeN, AnantharajaS, OliverN: Switching from flash glucose monitoring to continuous glucose monitoring on hypoglycemia in adults with type 1 diabetes at high hypoglycemia risk: the extension phase of the I HART CGM study. Diabetes Technol Ther, 2018; 20:751–757.
